Concordance with European League Against Rheumatism (EULAR) propositions for management of gout6 in hospitalized patients seen by a rheumatology service compared to controls. EULAR propositions 1–3 were not included as they could not be assessed in a retrospective study.
| EULAR Management Propositions | Seen by Rheumatology | p | |
|---|---|---|---|
| No = 59, n (%) | Yes = 79, n (%) | ||
| 4. Was an NSAID or oral colchicine used first? | 44 (74.6) | 35 (44.3) | < 0.001 |
| Used in presence of a contraindication? | 5 (8.5) | 6 (8.6) | 1.000 |
| 5. Was oral colchicine used? | 37 (62.7) | 31 (39.2) | 0.006 |
| Used at low dose? | 27 (73.0) | 27 (87.1) | 0.151 |
| Colchicine daily dose, mg | 1.8 ± 1.5 | 1.3 ± 1.0 | 0.070 |
| 6. Intraarticular steroid | 7 (11.9) | 35 (44.3) | < 0.001 |
| 7. Documentation that urate-lowering drug would be prescribed in patients with recurrent attacks, tophi, or radiographic changes? | 26/40 (65.0) | 46/57 (80.7) | 0.082 |
| 8. Documentation that urate-lowering drug would be titrated to achieve a goal urate level? | 8 (30.8) | 24 (53.3) | 0.066 |
| 9. Was allopurinol used as a urate-lowering drug (or plan to start?) | 26 (44.1) | 45 (78.9) | 0.134 |
| 10. Uricosuric agents prescribed | 0 | 2* (2.5) | 0.507* |
| 11. Prophylaxis against acute attacks during the first month of urate-lowering therapy? | 5/17 (29.4) | 23/38 (60.5) | 0.033 |
| 12. Was patient on a diuretic at the time of the attack? | 40 (67.8) | 50 (63.3) | 0.583 |
| Was the diuretic stopped? | 6 (15.0) | 4 (8.0) | 0.330 |
| Was the patient on losartan? | 4 (6.8) | 2 (2.5) | 0.402* |
| Was the patient on a fenofibrate? | 1 (1.7) | 1 (1.3) | 1.000* |
↵* One patient was taking probenecid with a plan to start allopurinol at a later date and a second was taking sulfinpyrazone.
* Fisher’s exact test. NSAID: nonsteroidal antiinflammatory drug.